AKHNATON

Wins by funder

Where the work is

EG · 52

Sources

The most recent award records behind the figures above. Every number on this page is computed from records like these — nothing is estimated or editorial.

• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 17 May 2020 · USD 95K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 17 May 2020 · USD 96K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 17 May 2020 · USD 97K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 17 May 2020 · USD 97K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 17 May 2020 · USD 89K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 17 May 2020 · USD 94K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 17 May 2020 · USD 97K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 17 May 2020 · USD 92K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 29 Dec 2019 · USD 99K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 29 Dec 2019 · USD 99K · World Bank
• the currently used drugs through the Egyptian national treatment program are combination of Sofosbuvir 400mg+ Daclatasvir 60 mg for 12 weeks . · 29 Dec 2019 · USD 99K · World Bank
• Purchase of Hepatitis c drugs for the treatment of patients who did not respond to prior direct-acting antiviral therapy according to the protocol approved by the NCCVH · 13 Nov 2019 · USD 98K · World Bank
• This is a fixed dose combination drug. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. · 13 Nov 2019 · USD 98K · World Bank
• Purchase of Hepatitis c drugs for the treatment of patients who did not respond to prior direct-acting antiviral therapy according to the protocol approved by the NCCVH · 13 Nov 2019 · USD 98K · World Bank
• Purchase of Hepatitis c drugs for the treatment of patients who did not respond to prior direct-acting antiviral therapy according to the protocol approved by the NCCVH · 13 Nov 2019 · USD 98K · World Bank
• Purchase of Hepatitis c drugs for the treatment of patients who did not respond to prior direct-acting antiviral therapy according to the protocol approved by the NCCVH · 13 Nov 2019 · USD 98K · World Bank
• Purchase of Hepatitis c drugs for the treatment of patients who did not respond to prior direct-acting antiviral therapy according to the protocol approved by the NCCVH · 13 Nov 2019 · USD 99K · World Bank
• Purchase of Hepatitis c drugs for the treatment of patients who did not respond to prior direct-acting antiviral therapy according to the protocol approved by the NCCVH · 13 Nov 2019 · USD 5K · World Bank
• Purchase of Hepatitis c drugs for the treatment of patients who did not respond to prior direct-acting antiviral therapy according to the protocol approved by the NCCVH · 13 Nov 2019 · USD 98K · World Bank
• Purchase of Hepatitis c drugs for the treatment of patients who did not respond to prior direct-acting antiviral therapy according to the protocol approved by the NCCVH · 13 Nov 2019 · USD 98K · World Bank